两组间患者的一般情况无显著性差异（见表1）。
表2显示在行心脏复律前夜和当天给予患者的术前用药。两组间的联合用药不存在显著性的差异（见表2）。
在依托咪酯诱导后60秒内，咪唑安定组20位患者中有2例（发生率为10%）出现肌阵颤，而安慰剂组20位患者中有10例（发生率为50%）发生肌阵颤。在咪唑安定组，出现肌阵颤的严重程度分级皆为轻度，而在安慰剂组，肌阵颤的严重程度分极为6例轻度，3例中度和1例重度。
两组间镇静评分和恢复时间在任何时间点都没有显著性差异（见表3）。没有患者抱怨在行心脏复律时有知晓记忆。
心脏复律的总成功率为75%。在试验期间出现的肌阵颤对心电图的解读没有影响。
华译网上海翻译公司曾经翻译过大量有关静脉注射低剂量咪唑安定减少依托咪酯引起的肌阵颤资料文件。Beijing Chinese Subtitling Translation Service Agency has translated many technical documents about Low-Dose Intravenous Midazolam Reduces Etomidate-Induced Myoclonus.
Patient characteristics were not significantly different between the groups (Table 1).
Table 2 lists medications given on the day before cardioversion and on the day of cardioversion. Regarding these co-medications, there were no significant differences between the study groups (Table 2).
Within 60 s after induction with etomidate, 2 of 20 patients (10%) in the midazolam group and 10 of 20 patients (50%) in the placebo group developed myoclonic movements. The intensity of myoclonus was graded as mild in both cases in the midazolam group and as mild in 6, moderate in 3, and severe in 1 patient in the placebo group.
At no time was there a significant difference in sedation score or in short-term recovery (Table 3). None of the patients complained about recall of cardioversion.
